Bio-Techne (BSP:T1CH34) 3-Year EBITDA Growth Rate : 8.10% (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Bio-Techne 3-Year EBITDA Growth Rate?

Bio-Techne's EBITDA per Share for the three months ended in Dec. 2024 was R$0.09.

During the past 12 months, Bio-Techne's average EBITDA Per Share Growth Rate was -17.80% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 8.10% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 8.20% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 8.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Bio-Techne was 85.00% per year. The lowest was -0.70% per year. And the median was 15.50% per year.

Competitive Comparison of Bio-Techne's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Bio-Techne's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bio-Techne's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bio-Techne's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Bio-Techne's 3-Year EBITDA Growth Rate falls into.

Save Embed

;

Save Embed

;

Bio-Techne 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Bio-Techne (BSP:T1CH34) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Bio-Techne 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Bio-Techne's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Bio-Techne Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Techne Corp (BSP:T1CH34) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

TECH:USA TE1:Germany

Address

614 McKinley Place N.E., Minneapolis, MN, USA, 55413

Website

https://www.bio-techne.com

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.

Bio-Techne Headlines

No Headlines